Takeda gets European panel nod for Alunbrig to treat lung cancer

The European Medicines Agency's Committee for Medicinal Products for Human Use recommended granting Japan-based Takeda's Alunbrig, or brigatinib, a marketing authorisation.

The panel's recommendations are generally followed by European regulators.

Alunbrig was approved last year by the U.S. Food and Drug Administration as a second-line treatment for patients with anaplastic lymphoma kinase-positive (ALK+) metastatic non-small cell lung cancer, who have progressed on or are intolerant to Pfizer drug crizotinib, the standard initial treatment for the disease.

(Reporting by Sangameswaran S in Bengaluru; Editing by Sai Sachin Ravikumar)